Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211831 | 0.93 | ALDH1A1 (0.32) | — | |
| Acetic Acid SCHEMBL2831687 | 0.77 | FFAR3 (0.39) | CTH | |
| Acetic Acid SCHEMBL15941596 | 0.75 | FFAR3 (0.41) | CTH | |
| Acetic Acid SCHEMBL1136273 | 0.75 | FFAR3 (0.41) | CTH | |
| Acetic Acid SCHEMBL2635726 | 0.75 | FFAR3 (0.41) | CTH | |
| Acetic Acid SCHEMBL7171704 | 0.75 | FFAR3 (0.41) | CTH | |
| SCHEMBL12478731 | 0.73 | — | — | |
| Trifluoroacetic Acid SCHEMBL3957738 | 0.72 | CES2 (0.34) | CTH | |
| SCHEMBL30914641 | 0.71 | CYP4F2 (0.31) | — | |
| SCHEMBL28656011 | 0.71 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106749613-A | A kind of synthetic method of Suo Malu peptides | 江苏诺泰生物制药股份有限公司 | 2017-05-31 | — | — | CN | claimed |
| US-12622948-B2 | GLP-1/GIP dual agonists | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2026-05-12 | — | — | US | disclosed |
| EP-4724471-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724472-A2 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | disclosed |
| US-20250019410-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-01-16 | — | — | US | disclosed |
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2024-12-26 | — | — | US | disclosed |
| WO-2024252366-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024252367-A2 | NOVEL GLP-1/GIP DUAL AND GLP-1/GCG DUAL RECEPTOR AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-12-12 | — | — | WO | disclosed |
| US-20240400613-A1 | GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2024-12-05 | — | — | US | disclosed |
| EP-4436991-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Sun Pharmaceutical Industries Limited (IN) | 2024-10-02 | — | — | EP | disclosed |
| US-20230241178-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2023-08-03 | — | — | US | disclosed |
| EP-4204440-A1 | GLP-1/GIP DUAL AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023089594-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2023-05-25 | — | — | WO | disclosed |
| EP-4146248-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022079639-A1 | GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-04-21 | — | — | WO | disclosed |
| CN-106749613-A | A kind of synthetic method of Suo Malu peptides | 江苏诺泰生物制药股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241178-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | CTH 3733/4885 |
| US-20240400613-A1 | GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | CTH 3639/4885 |
| US-12622948-B2 | GLP-1/GIP dual agonists | GLP1R, GIPR, NPY4R | CTH 682/4885 |
| US-20250019410-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SYK, TREH, QDPR | CTH 1408/4885 |
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | CTH 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.